- Home
- OMER
OMER
Omeros Corporation
as 10-23-2025 3:54pm EST
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 274.3M | IPO Year: | 2009 |
| Target Price: | $27.50 | AVG Volume (30 days): | 8.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.95 - $13.60 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Omeros Corporation News
OMER Breaking Stock News: Dive into OMER Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Omeros Sells Exclusive Global Rights for Drug Zaltenibart to Novo Nordisk
Simply Wall St.
6 days ago
Can Novo Nordisk’s (CPSE:NOVO B) Rare Disease Deal Reshape Its Long-Term Growth Story?
Pharmaceutical Technology
8 days ago
Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
Zacks
8 days ago
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
Business Wire
8 days ago
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
Motley Fool
8 days ago
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Investor's Business Daily
9 days ago
Omeros Catapults 154% On A Surprise $2.1 Billion Deal With Novo Nordisk
Barchart
9 days ago
Novo Nordisk Just Signed a Key Drug Deal With Omeros. Is There Any Room Left for OMER Stock to Run?
Compare OMER vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OMER Omeros Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.